Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-DLL3 bispecific antibody RO7616789

A bispecific T-cell engager antibody directed against both the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) and an as of yet unspecified antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-DLL3 bispecific antibody RO7616789 binds to both the antigen on cytotoxic T lymphocytes (CTLs) and the DLL3 antigen on DLL3-expressing tumor cells. This activates and redirects CTLs to DLL3-expressing tumor cells, which results in the CTL-mediated cell death of DLL3-expressing tumor cells. DLL3, a Notch pathway protein, is overexpressed on a variety of cancer cell types. It plays a key role in embryonic development and in tumor initiation and proliferation.
Code name:RO 7616789
RO-7616789
RO7616789
Search NCI's Drug Dictionary